Makoto Akimoto
Chiyoda, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis.
Journal: Clinical therapeutics
Published: June 28, 2023
Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants.
Journal: Clinical therapeutics
Published: July 04, 2022
Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults.
Journal: Clinical pharmacology in drug development
Published: November 23, 2020
Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
Journal: Clinical therapeutics
Published: April 08, 2020
A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: December 25, 2019
An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment.
Journal: Clinical therapeutics
Published: October 23, 2019
Edaravone and its clinical development for amyotrophic lateral sclerosis.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: September 06, 2017
Edaravone for treatment of early-stage ALS - Authors' reply.
Journal: The Lancet. Neurology
Published: August 07, 2017
Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.
Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration
Published: October 07, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026